Revlimid® (lenalidomide): New important advice regarding viral reactivation

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 13 April 2017

 

Description:

Cases of viral reactivation have been reported following treatment with lenalidomide, particularly in patients previously infected with the varicella zoster or hepatitis B viruses (HBV). Some cases of HBV reactivation progressed to acute hepatic failure and resulted in death. As such, hepatitis B virus status should be established before initiating treatment with lenalidomide and a physician with expertise in the treatment of hepatitis B should be consulted for patients who test positive for HBV infection. For previously infected patients, they should be closely monitored for signs and symptoms of viral reactivation, including active HBV infection, throughout therapy. Please refer to the Direct Healthcare Professional Communication (DHPC) issued by Celgene Sdn. Bhd. in agreement with NPRA for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA